Expert Interviews

Dr Jennifer Brigitte Green addresses clinical considerations for patients with type 2 diabetes who are not responding to their oral antidiabetic agents and discusses her strategy for insufficient target glycemic control with insulin regimens.

Closing out his discussion on CGP, David Gandara, MD, looks toward future opportunities for CGP in screening patients before or after surgery.

Considering the value of comprehensive genomic profiling, David Gandara, MD, highlights the importance of supporting access to testing.

A brief discussion on the value of commercially available comprehensive genomic profiling over homegrown testing.

In this interview, Briana Contreras, associate editor of Managed Healthcare Executive, spoke with Shara Cohen, CEO of Carallel, an organization built to support caregivers. Cohen not only spoke about who caregivers are and the vital role they play in healthcare, but the challenges they face. She also discussed ways health plans can do better to meet the needs of today’s caregivers.

David Gandara, MD, explains how the scope of comprehensive genomic profiling has shifted from a select few patients to the majority.

A review of how comprehensive genomic profiling can better inform treatment planning and alleviate health care economic burden.

Current strategies used to evaluate the performance of therapies used to treat atopic dermatitis and guide formulary decisions, and recommendations to help patients receive access to effective therapies.

Payer and clinician insight regarding access to effective therapies for atopic dermatitis and potential challenges adopting new therapies, including topical JAK inhibitors, into clinical practice.

An overview of limitations faced by payers and clinicians who play a role in the management of atopic dermatitis.

Expert perspective on clinical and personal improvements in cancer care made available by appropriate use of comprehensive genomic profiling.

David Gandara, MD, focuses on the differences between liquid biopsy and tissue-based CGP, suggesting a role for both in the current treatment landscape.

Clinician Moti Ramgopal, MD, FACP, FIDSA, highlights key components of a successful HIV PrEP program and comments on the role of providers in introducing these components throughout a patient’s continuum of care to maximize outcomes.

Jennifer Brigitte Green, MD, reviews her treatment approach for managing patients with type 2 diabetes and shares insight on how to identify patients that are uncontrolled with oral antidiabetic agents.

Drs Shah and Lio explore where topical ruxolitinib fits into therapeutic sequencing in atopic dermatitis, compared with oral JAK inhibitors.

Dr Lio discusses features that make JAK inhibitors, including ruxolitinib, abrocitinib, baricitinib, and upadacitinib, attractive in the management of atopic dermatitis.

Variables considered when developing and referring to treatment formularies for atopic dermatitis.

A clinical expert shared insight on the evolution of comprehensive genomic profiling and how it has impacted cancer care.

An overview of topical and oral therapies used to treat mild-to-moderate atopic dermatitis.

Considerations for quality measures established for atopic dermatitis when assessing how well patients are responding to treatment.

Indirect costs associated with atopic dermatitis, and the financial burden associated with delayed treatment initiation or inappropriate therapy.

The impact atopic dermatitis and associated comorbidities have on patients with the condition, as well as family members.

An overview of what has been learned over time that can help dermatologists and other community physicians appropriately identify signs of atopic dermatitis in children and adults.

Managed Healthcare Executive® recently interviewed Jacqueline Glascock, Ph.D., the director of research programs at Cure SMA, an nonprofit organization in Elk Grove, Illinois, that funds research into spinal muscular atrophy (SMA) and advocates for families and patients. In this video, Glascock discusses SMA and her organization, the three current therapies for the disease, and a combination therapy approach to the disease.

Ray Tancredi, divisional vice president of specialty pharmacy development and brand rx/vaccine purchasing at Walgreens, will be speaking at Asembia's 2021 Specialty Pharmacy Summit. In this video Tancredi talks about the drugs that are most significant in the pipeline and what to look for in approvals in the future.

Michelle Booth, Pharm.D., of Magellan Rx Management, is speaking at this year's Asembia Specialty Pharmacy Summit. In this clip Booth speaks about trends in drug spend and the differences among the commercial, Medicare and Medicaid lines of business.

Jim Adams, chief information officer of AllianceRx Walgreens Prime, is a speaker at the 2021 Asembia Specialty Pharmacy Summit. In this clip Adams talks about the relationship between his organization and Walgreens, how telehealth can improve the health of specialty pharmacy patients and more.

Heather Bonome, Pharm.D., pharmacy director at URAC, a healthcare accreditation organization, is a speaker at the 2021 Asembia Specialty Pharmacy Summit. Bonome talks about a defining telehealth, the pandemic's effect on the use of telehealth in specialty pharmacy and whether URAC might add telehealth requirements to its accrediting standards for specialty pharmacies.

George Van Antwerp, pharmacy and PBM leader of Deloitte, presents at the Asembia 2021 Specialty Pharmacy Summit and shares framework of specialty pharmacy.

Steve Peskin of Horizon BCBS of NJ, executive medical director of Population Health at Horizon Blue Cross Blue Shield of New Jersey, shares forms of value-based contracting between payers and pharmaceutical companies.